Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke

European Neurology

Volumn 74, Issue 3-4, 2015, Pages 127-134

  Laible, Mona ^a   Jenetzky, Ekkehardt ^b,c,d   Möhlenbruch, Markus ^a   Ringleb, Peter Arthur ^a   Rizos, Timolaos ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d Hospital for Paediatric Neurology and Social Paediatrics   (Germany)

Author keywords

Outcome; Recurrent stroke; Repeated intravenous thrombolysis; Safety; sICH

Indexed keywords

FIBRINOLYTIC AGENT; PLAT PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PROCEDURES; RETREATMENT; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETREATMENT; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84941765022     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000439048     Document Type: Article

References (34)

1. Kwiatkowski TG, Libman RB, Frankel M, et al: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340: 1781-1787.
2. Qureshi AI, Suri MF, Nasar A, et al: Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999-2001. Neurosurgery 2005; 57: 647-654; discussion 647-654.
3. Deng YZ, Reeves MJ, Jacobs BS, et al: IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology 2006; 66: 306-312.
4. Katzan IL, Hammer MD, Hixson ED, et al: Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346-350.
5. World Population Prospects, the 2008 Revision. New York, United Nations Population Division, 2009.
6. Lindsberg PJ, Häppölä O, Kallela M, et al: Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology 2006; 67: 334-336.
7. De Los Rios F, Kleindorfer DO, Guzik A, et al: Intravenous fibrinolysis eligibility: A survey of stroke clinicians' practice patterns and review of the literature. J Stroke Cerebrovasc Dis 2014; 23: 2130-2138.
8. Heldner MR, Mattle HP, Jung S, et al: Thrombolysis in patients with prior stroke within the last 3 months. Eur J Neurol 2014; 21: 1493-1499.
9. Montaño A, Staff I, McCullough LD, et al: Community implementation of intravenous thrombolysis for acute ischemic stroke in the 3-To 4.5-hour window. Am J Emerg Med 2013; 31: 1707-1709.
10. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
11. Prabhakaran S, McNulty M, O'Neill K, et al: Intravenous thrombolysis for stroke increases over time at primary stroke centers. Stroke 2012; 43: 875-877.
12. Adeoye O, Hornung R, Khatri P, et al: Recombinant tissue-Type plasminogen activator use for ischemic stroke in the United States: A doubling of treatment rates over the course of 5 years. Stroke 2011; 42: 1952-1955.
13. European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits. http://controlledtrials. com/ISRCTN71616222?close=1 (accessed October 5, 2015).
14. Seshadri S, Beiser A, Kelly-Hayes M, et al: The lifetime risk of stroke: estimates from the Framingham study. Stroke 2006; 37: 345-350.
15. Gloede TD, Halbach SM, Thrift AG, et al: Long-Term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke 2014; 45: 3389-3394.
16. Banerjee P, Clark AL, Norell MS: Repeat thrombolysis for acute myocardial infarction. Int J Cardiol 2005; 102: 515-519.
17. Cugno M, Cicardi M, Colucci M, et al: Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost 1996; 76: 234-238.
18. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
19. Sauer R, Huttner HB, Breuer L, et al: Repeated thrombolysis for chronologically separated ischemic strokes: A case series. Stroke 2010; 41: 1829-1832.
20. Nicoli F, Faivre A, Squarcioni C, et al: Repeated MR-based intravenous thrombolysis in a patient with short interval stroke recurrences. J Neuroradiol 2011; 38: 256-258.
21. Cappellari M, Moretto G, Bovi P: Repeated intravenous thrombolysis after recurrent stroke. A case series and review of the literature. J Neurol Sci 2014; 345: 181-183.
22. Yoo HS, Kim YD, Lee HS, et al: Repeated thrombolytic therapy in patients with recurrent acute ischemic stroke. J Stroke 2013; 15: 182-188.
23. Topakian R, Gruber F, Fellner FA, et al: Thrombolysis beyond the guidelines: Two treatments in one subject within 90 hours based on a modified magnetic resonance imaging brain clock concept. Stroke 2005; 36:e162-e164.
24. Sposato LA, Salutto V, Beratti DE, et al: Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis. Case Rep Vasc Med 2013; 2013: 371642.
25. Nicoli F, Faivre A, Squarcioni C, et al: Repeated MR-based intravenous thrombolysis in a patient with short interval stroke recurrences. J Neuroradiol 2011; 38: 256-258.
26. Cambron M, Van Hooff RJ, Nieboer K, et al: Successful repetitive intravenous thrombolysis in a patient with recurrent brainstem infarctions due to megadolichobasilar ectasia. JAMA Neurol 2013; 70: 520-521.
27. Wahlgren N, Ahmed N, Dávalos A, et al: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007; 369: 275-282.
28. Adams HP Jr, Bendixen BH, Kappelle LJ, et al: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
29. Lovett JK, Coull AJ, Rothwell PM: Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 24: 569-573.
30. Wahlgren N, Ahmed N, Dávalos A, et al: Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study. Lancet 2008; 372: 1303-1309.
31. Fonarow GC, Smith EE, Saver JL, et al: Timeliness of tissue-Type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-To-needle times within 60 min. Circulation 2011; 123: 750-758.
32. Lin SY, Tang SC, Tsai LK, et al: Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. Eur J Neurol 2014; 21: 1285-1291.
33. Rudolf J, Grond M, Schmülling S, et al: Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology 2000; 55: 599-600.
34. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP: The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-1457.